Skip to main content
SpringerLink
Log in

Very low levels of vitamin D in systemic sclerosis patients

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Vitamin D displays many extraosseous immunomodulatory effects. The aim of the study was to evaluate the level of vitamin D in patients with systemic sclerosis (SSc) and to analyze the associations between the concentration of the vitamin and clinical manifestations. In March-April 2009, 65 consecutive SSc patients underwent evaluation of vitamin D concentrations by the LIAISON immunoassay (normal 30-100 ng/ml). Serum levels between 10 and 30 ng/ml were classified as vitamin D insufficiency, while concentrations <10 ng/ml as vitamin D deficiency. None of the patients were receiving vitamin D supplementation at the time of or during the year prior to study entry. The mean level of vitamin D was 15.8 ± 9.1 ng/ml. Only three cases showed normal values; vitamin D insufficiency and deficiency were found in 43 and 19 cases, respectively. Patients with vitamin D deficiency showed longer disease duration (13.1 ± 6.8 versus 9.4 ± 5.5 years, P = 0.026), lower diffusing lung capacity for carbon monoxide (63.7 ± 12.4 versus 76.4 ± 20.2, P = 0.014), higher estimated pulmonary artery pressure (28.9 ± 9.9 versus 22.8 ± 10.4, P = 0.037) and higher values of ESR (40 ± 25 versus 23 ± 13 mm/h, P = 0.001) and of CRP (7 ± 7 and 4 ± 2 mg/l, P = 0.004) in comparison with patients with vitamin D insufficiency; moreover, late nailfold videocapillaroscopic pattern was more frequently found (52.6% versus 18.6%, P = 0.013). None of the patients showed evidence of overt mal-absorption. Low levels of vitamin D are very frequent in patients with SSc. Intestinal involvement is not likely the cause of vitamin D deficit; other factors such as skin hyperpigmentation and reduced sun exposition for psychological and social reasons may be implicated. Patients with vitamin D deficiency showed more severe disease in comparison with patients with vitamin D insufficiency, above all concerning lung involvement. Further trials are awaited to determine whether vitamin D could represent a modifiable factor able to interfere with SSc evolution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662–687

    Article  CAS  PubMed  Google Scholar 

  2. Szodoray P, Nakken B, Gaal J et al (2008) The complex role of vitamin D in autoimmune diseases. Scand J Immunol 68:261–269

    Article  CAS  PubMed  Google Scholar 

  3. Wu PW, Rhew EY, Dyer AR et al (2009) 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum 61:1387–1395

    Article  CAS  PubMed  Google Scholar 

  4. Wright TB, Shults J, Zemel LMB, BS BJM (2009) Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 155:260–265

    Article  CAS  PubMed  Google Scholar 

  5. Veldman CM, Cantorna MT, Luca HF DE (2000) Expression of 1, 25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys 374:334–338

    Article  CAS  PubMed  Google Scholar 

  6. Morgan JW, Kouttab N, Ford D, Maizel AL (2000) Vitamin D-mediated gene regulation in phenotypically defined B cells sub-populations. Endocrinology 141:3225–3234

    Article  CAS  PubMed  Google Scholar 

  7. Lemire JM, Archer DC (1991) 1, 25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87:1103–1107

    Article  CAS  PubMed  Google Scholar 

  8. de Abreu DA Fernandes, Eyles D, Feron F (2009) Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psyconeuroendocrinology 34(suppl 1):S265–S277

    Article  Google Scholar 

  9. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Article  Google Scholar 

  10. LeRoy EC, Black CM, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

    CAS  PubMed  Google Scholar 

  11. Akesson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR (2003) Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 21(suppl 29):S5–S8

    CAS  PubMed  Google Scholar 

  12. Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–8

    Article  CAS  PubMed  Google Scholar 

  13. Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155–160

    CAS  PubMed  Google Scholar 

  14. Medsger TA Jr, Bombardieri S, Czjriak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(suppl 29):S42–6

    PubMed  Google Scholar 

  15. Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y (2009) Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with Systemic Sclerosis. J Rheumatol 36:1924–1929

    Article  CAS  PubMed  Google Scholar 

  16. Dovio A, Data V, Carignola R et al (2008) Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis. J Rheumatol 35:2206–2213

    Article  CAS  PubMed  Google Scholar 

  17. Braun-Moscovici Y, Furst DE, Markovits D et al (2008) Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J Rheumatol 35:2201–2205

    Article  CAS  PubMed  Google Scholar 

  18. Orbach H, Zandman-Goddard G, Amital H et al (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109:385–400

    Article  CAS  PubMed  Google Scholar 

  19. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS (2006) Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 5:114–117

    Article  CAS  PubMed  Google Scholar 

  20. Zold E, Szodoray P, Gaal J et al (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123

    Article  PubMed  Google Scholar 

  21. Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577–582

    Article  CAS  PubMed  Google Scholar 

  22. Bryan C, Howard Y, Brennan P, Black Cm, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35:1122–6

    Article  CAS  PubMed  Google Scholar 

  23. Matucci-Cerinic M, D’Angelo S, Denton CP, Vlachoyannopoulos P, Silver R (2003) Assessment of lung involvement. Clin Exp Rheumatol 21(suppl 29):S19–S23

    CAS  PubMed  Google Scholar 

  24. Artaza JN, Norris KC (2009) Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 200:207–221

    Article  CAS  PubMed  Google Scholar 

  25. Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zugel U, Roman J (2010) Vitamin D inhibition of pro-fibrotic effects on transforming growth factor β1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 118:142–150

    Article  CAS  PubMed  Google Scholar 

  26. Willis BC, Liebler JM, Luby-Phelps K et al (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166:1321–1332

    CAS  PubMed  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy

    Paola Caramaschi, Alessandra Dalla Gassa, Viviana Ravagnani, Ilaria Tinazzi, Giovanni Barausse, Lisa M. Bambara & Domenico Biasi

  2. Dipartimento di Scienze Morfologico-Biomediche, Università di Verona, Verona, Italy

    Orazio Ruzzenente

  3. Dipartimento di Medicina Interna, Ospedale di Negrar (Verona), Verona, Italy

    Alessandro Volpe

  4. Dipartimento di Medicina Clinica e Sperimentale, Policlinico G.B. Rossi, Piazzale Scuro, 37134, Verona, Italy

    Paola Caramaschi

Authors
  1. Paola Caramaschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Dalla Gassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orazio Ruzzenente
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Viviana Ravagnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ilaria Tinazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanni Barausse
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lisa M. Bambara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Domenico Biasi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paola Caramaschi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caramaschi, P., Dalla Gassa, A., Ruzzenente, O. et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 29, 1419–1425 (2010). https://doi.org/10.1007/s10067-010-1478-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1478-3

Keywords

Search

Navigation